ログイン
ランキング
お知らせ
ログイン
文献詳細
文献概要
特集 循環器の現場からの検証：そのエビデンスを日本で活用するには？ Ⅱ．予防医療
ハイリスク冠動脈疾患患者に対する低用量抗凝固療法—COMPASS試験をどう現場に落とし込むか？
著者： 堀正二1
所属機関： 1地方独立行政法人大阪府立病院機構大阪国際がんセンター
ページ範囲：P.60 - P.67
文献購入ページに移動Point
・COMPASS試験はハイリスク冠動脈疾患・末梢血管疾患を対象にしたアスピリンと少量リバーロキサバン（2.5mg bid）の併用の有効性を検証した大規模臨床試験である．
・COMPASS試験においてハイリスク冠動脈疾患の2次予防にアスピリンと少量DOAC併用が有用であることが示された．
・ハイリスク末梢血管疾患には特に大きな有効性が認められた．
・この併用療法は，出血リスクが増大するので，軽症の冠動脈疾患・末梢血管疾患には適応がないと考えられる．
・COMPASS試験はハイリスク冠動脈疾患・末梢血管疾患を対象にしたアスピリンと少量リバーロキサバン（2.5mg bid）の併用の有効性を検証した大規模臨床試験である．
・COMPASS試験においてハイリスク冠動脈疾患の2次予防にアスピリンと少量DOAC併用が有用であることが示された．
・ハイリスク末梢血管疾患には特に大きな有効性が認められた．
・この併用療法は，出血リスクが増大するので，軽症の冠動脈疾患・末梢血管疾患には適応がないと考えられる．
参考文献
1) Bhatt DL, Eagle KA, Ohman EM, et al:Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304:1350-1357, 2010
2) Antithrombotic Trialists'（ATT）Collaboration Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomized trials. Lancet 373:1849-1860, 2009
3) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002
4) CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events（CAPRIE）. Lancet 348:1329-1339, 1996
5) Bhatt DL, Fox KA, Hacke W, et al:Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-1717, 2006
6) Anand SS, Yusuf S:Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 41（4 Suppl S）:62S-69S, 2003
7) Andreotti F, Testa L, Biondi-Zoccai GG, Crea F:Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes:an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27:519-526, 2006
8) Merlini PA, Bauer KA, Oltrona L, et al:Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61-68, 1994
9) Rothberg MB, Celestin C, Fuore LD, et al:Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome:meta-analysis with estimates of risk and benefit. Ann Intern Med 143:241-250, 2005
10) Wallentin L, Wilcox RG, Weaver WD, et al:Oral ximelagatran for secondary prophylaxis after myocardial infarction:the ESTEEM randomized controlled trial. Lancet 362:789-797, 2003
11) Mega JL, Braunwald E, Mohanavelu S, et al:Rivaroxaban versus placebo in patients with acute coronary syndromes（ATLAS ACS-TIMI 46）:a randomized, double-blind, phase II trial. Lancet 374:29-38, 2009
12) Mega JL, Braunwald E, Wiviott SD, et al:ATLAS ACS-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndromes N Engl J Med 366:9-19, 2012
13) Bosch J, Eikelboom JW, Connolly SJ, et al:Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies（COMPASS）trial. Can J Cardiol 33:1027-1033, 2017
14) Eikelboom JW, Conolly SJ, Bosch J, et al:Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319-1330, 2017
15) Connoly SJ, Eikelboom JW, Bosch J, et al:Rivaroxaban with or without aspirin In patients with stable coronary artery disease:an international, randomized, double-blind, placebo-controlled trial. Lancet 391:205-218, 2018
16) Anand SS, Bosch J, Eikelboom JW, et al:Rivaroxaban with or without aspirin in patients with stable coronary artery disease:an international, randomized, double-blind, placebo-controlled trial Lancet 391:219-229, 2018
17) Anand SS, Yusuf S, Xie C, et al:Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357:217-227, 2007
18) Hess CN, Norgren L, Ansel GM, et al:A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization:a TASC（InterSociety Consensus for the Management of Peripheral Artery Disease）initiative. Circulation 135:2534-2555, 2017
19) Baerger JS, Krants MJ, Kittelson JM, Hiatt WR:Aspirin for the prevention of a Cardiovascular events in patients with peripheral artery disease:a meta-analysis of randomized trials. JAMA 301:1909-1919, 2009
20) Bonaca MP, Bhatt DL, Storey RF, et al:Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 67:2719-2728, 2016
21) Morrow DA, Braunwald E, Bonaca MP, et al:Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404-1413, 2012
掲載誌情報
